Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy

Oral Oncology

Volumn 44, Issue 1, 2008, Pages 23-30

  Guo, Ye ^a   Lu, Jiade J ^b   Ma, Xuejun ^a   Wang, Biyun ^a   Hong, Xiaonan ^a   Li, Xiaoqiu ^a   Li, Jin ^a  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Chemotherapy; Nasal NK T cell lymphoma; Nitrosourea; Radiation therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; NITROSOUREA; PREDNISONE; SEMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; ELECTROCORTICOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; FRACTIONATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NATURAL KILLER T CELL; NOSE CAVITY; NOSE CAVITY CANCER; NOSE SEPTUM; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOMUSTINE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; RETROSPECTIVE STUDIES; SEMUSTINE; SURVIVAL RATE;

EID: 37049021104     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.11.020     Document Type: Article

References (35)

1. Cuadra-Garcia I., Proulx G.M., Wu C.L., et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 23 (1999) 1356-1369
2. Proulx G.M., Caudra-Garcia I., Ferry J., et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 26 (2003) 6-11
3. Ko Y.H., Kim C.W., Park C.S., et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Cancer 83 (1998) 806-812
4. Au W.Y., Ma S.Y., Chim C.S., et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16 (2005) 206-214
5. Kim W.S., Song S.Y., Ahn Y.C., et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 12 (2001) 349-352
6. Aviles A., Neri N., Fernadez R., et al. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 20 (2004) 13-17
7. You J.Y., Chi K.H., Yang M.H., et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 15 (2004) 618-625
8. Lee J.Y., Park Y.H., Kim W.S., et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41 (2005) 1402-1408
9. Kim T.M., Park Y.H., Lee S.Y., et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 106 (2005) 3785-3790
10. Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer T-cell lymphoma. J Clin Oncol 24 (2006) 181-189
11. Palmieri G., Lauria R., Caponigro F., et al. Salvage chemotherapy for non Hodgkin's lymphoma of unfavorable histology with a combination of CCNU and vinblastine. Hematol Oncol 8 (1990) 179-183
12. Dorigo A., Mansberg R., and Kwan Y.L. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. Eur J Haematol 50 (1993) 37-40
13. Shamash J., Walewski J., Apostolidis J., et al. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol (2000) 857-860
14. Musolino A., Perrone M.A., Michiara M., et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 103 (2005) 2109-2117
15. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3839
16. Ng C.S., Chan J.K.C., Lo S.T.H., et al. Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 18 (1987) 1257-1262
17. Chan J.K.C., Ng C.S., Tsang W.Y.W., et al. Discordant CD3 expression in lymphomas as studied on frozen and paraffin sections. Hum Pathol (1995) 1139-1143
18. Kwong Y.L., Chan A.C.L., Liang R., et al. CD 56 NK lymphomas: clinicopathological features and prognosis. Br J Haematol 97 (1997) 821-829
19. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
20. Cox D.R. Regression models and life-tables. J Stat Soc 34 (1982) 187-220
21. Lee J., Kim W.S., Park Y.H., et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 92 (2005) 1226-1230
22. Kim B.S., Kim T.Y., Kim C.W., et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy. Acta Oncol 42 (2003) 779-783
23. Cheung M.M.C., Chan J.K.C., Lau W.H., et al. Early stage nasal NK/T-cell lymphoma clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54 (2002) 182-190
24. Lee J., Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 20 (2006) 612-618
25. Chim C.S., Ma S.H., Au W.Y., et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 103 (2004) 216-221
26. Kim G.E., Lee S.W., Chang S.K., et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 61 (2001) 261-269
27. Li C.C., Tien H.F., Tang J.L., et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 100 (2004) 366-375
28. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphomas Study Group. Blood 84 (1994) 1361-1392
29. Miller T.P., Dahlberg S., Cassady R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
30. Kim K., Chie E.K., Kim C.W., et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 35 (2005) 1-5
31. Tham I.W.K., Lee K.M., Yap S.P., et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck 28 (2006) 126-134
32. Shipp M.A., Harrington D.P., Anderson J.R., et al. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
33. Ansell S.M., Habermann T.M., Kurtin P.J., et al. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol 15 (1997) 2296-2301
34. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
35. Egashira M., Kawamata N., Sugimoto K., et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93 (1999) 599-606